Top

Breast Cancer Research and Treatment

Published in:

01-07-2018 | Preclinical study

Characterizing the efficacy of cancer therapeutics in patient-derived xenograft models of metastatic breast cancer

Authors: Tia H. Turner, Mohammad A. Alzubi, Sahib S. Sohal, Amy L. Olex, Mikhail G. Dozmorov, J. Chuck Harrell

Published in: Breast Cancer Research and Treatment | Issue 2/2018

Abstract

Purpose

Basal-like breast cancers are aggressive and often metastasize to vital organs. Treatment is largely limited to chemotherapy. This study aims to characterize the efficacy of cancer therapeutics in vitro and in vivo within the primary tumor and metastatic setting, using patient-derived xenograft (PDX) models.

Methods

We employed two basal-like, triple-negative PDX models, WHIM2 and WHIM30. PDX cells, obtained from mammary tumors grown in mice, were treated with twelve cancer therapeutics to evaluate their cytotoxicity in vitro. Four of the effective drugs—carboplatin, cyclophosphamide, bortezomib, and dacarbazine—were tested in vivo for their efficacy in treating mammary tumors, and metastases generated by intracardiac injection of tumor cells.

Results

RNA sequencing showed that global gene expression of PDX cells grown in the mammary gland was similar to those tested in culture. In vitro, carboplatin was cytotoxic to WHIM30 but not WHIM2, whereas bortezomib, dacarbazine, and cyclophosphamide were cytotoxic to both lines. Yet, these drugs were ineffective in treating both primary and metastatic WHIM2 tumors in vivo. Carboplatin and cyclophosphamide were effective in treating WHIM30 mammary tumors and reducing metastatic burden in the brain, liver, and lungs. WHIM2 and WHIM30 metastases showed distinct patterns of cytokeratin and vimentin expression, regardless of treatment, suggesting that different tumor cell subpopulations may preferentially seed in different organs.

Conclusions

This study highlights the utility of PDX models for studying the efficacy of therapeutics in reducing metastatic burden in specific organs. The differential treatment responses between two PDX models of the same intrinsic subtype, in both the primary and metastatic setting, recapitulates the challenges faced in treating cancer patients and highlights the need for combination therapies and predictive biomarkers.

Available only for authorised users

Howlader N, Noone A, Krapcho M, et al (2017) SEER cancer statistics review (CSR), 1975–2014. In: Natational Cancer Institute https://seer.cancer.gov/csr/1975_2014/. Accessed 5 Feb 2017

Dent R, Trudeau M, Pritchard KI et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13:4429–4434. https://doi.org/10.1158/1078-0432.CCR-06-3045 CrossRefPubMed

Jitariu A-A, Cîmpean AM, Ribatti D, Raica M (2015) Triple negative breast cancer: the kiss of death. Oncotarget. https://doi.org/10.18632/oncotarget.16938 CrossRef

Perou CM, Sørlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752. https://doi.org/10.1038/35021093 CrossRefPubMed

Prat A, Perou CM (2011) Deconstructing the molecular portraits of breast cancer. Mol Oncol 5:5–23. https://doi.org/10.1016/j.molonc.2010.11.003 CrossRefPubMed

Curtis C, Shah SP, Chin S-F et al (2012) The genomic and transcriptomic architecture of 2000 breast tumours reveals novel subgroups. Nature 486:346–352. https://doi.org/10.1038/nature10983 CrossRefPubMedPubMedCentral

Koboldt DC, Fulton RS, McLellan MD et al (2012) Comprehensive molecular portraits of human breast tumours. Nature 490:61–70. https://doi.org/10.1038/nature11412 CrossRef

Sørlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869–10874. https://doi.org/10.1073/pnas.191367098 CrossRefPubMedPubMedCentral

van’t Veer LJ, Dai H, van de Vijver MJ et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530–536. https://doi.org/10.1038/415530a CrossRef

10.

Sørlie T (2004) Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. Eur J Cancer 40:2667–2675. https://doi.org/10.1016/j.ejca.2004.08.021 CrossRefPubMed

11.

Harrell JC, Aleix P, Parker JS et al (2012) Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse. Breast Cancer Res Treat 132:523–535. https://doi.org/10.1007/s10549-011-1619-7 CrossRefPubMed

12.

Lin NU, Claus E, Sohl J et al (2008) Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer. Cancer 113:2638–2645. https://doi.org/10.1002/cncr.23930 CrossRefPubMedPubMedCentral

13.

Dent R, Hanna WM, Trudeau M et al (2009) Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat 115:423–428. https://doi.org/10.1007/s10549-008-0086-2 CrossRefPubMed

14.

Houghton JA, Houghton PJ, Green AA (1982) Chemotherapy of childhood rhabdomyosarcomas growing as xenografts in immune-deprived mice. Cancer Res 42:535–539PubMed

15.

Fiebig HH, Neumann HA, Henss H et al (1985) Development of three human small cell lung cancer models in nude mice. Recent Results Cancer Res 97:77–86CrossRefPubMed

16.

Fichtner I, Slisow W, Gill J et al (2004) Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas. Eur J Cancer 40:298–307CrossRefPubMed

17.

Fichtner I, Rolff J, Soong R et al (2008) Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin Cancer Res 14:6456–6468. https://doi.org/10.1158/1078-0432.CCR-08-0138 CrossRefPubMed

18.

Daniel VC, Marchionni L, Hierman JS et al (2009) A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res 69:3364–3373. https://doi.org/10.1158/0008-5472.CAN-08-4210 CrossRefPubMedPubMedCentral

19.

Tentler JJ, Tan AC, Weekes CD et al (2012) Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol 9:338–350. https://doi.org/10.1038/nrclinonc.2012.61 CrossRefPubMedPubMedCentral

20.

Siolas D, Hannon GJ (2013) Patient-derived tumor xenografts: transforming clinical samples into mouse models. Cancer Res 73:5315–5319. https://doi.org/10.1158/0008-5472.CAN-13-1069 CrossRefPubMedPubMedCentral

21.

Hidalgo M, Amant F, Biankin AV et al (2014) Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov 4:998–1013. https://doi.org/10.1158/2159-8290.CD-14-0001 CrossRefPubMedPubMedCentral

22.

Choi YY, Lee JE, Kim H et al (2016) Establishment and characterisation of patient-derived xenografts as paraclinical models for gastric cancer. Sci Rep 6:22172. https://doi.org/10.1038/srep22172 CrossRefPubMedPubMedCentral

23.

DeRose YS, Wang G, Lin Y-C et al (2011) Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med 17:1514–1520. https://doi.org/10.1038/nm.2454 CrossRefPubMedPubMedCentral

24.

Huang K, Li S, Mertins P et al (2017) Proteogenomic integration reveals therapeutic targets in breast cancer xenografts. Nat Commun 8:14864. https://doi.org/10.1038/ncomms14864 CrossRefPubMedPubMedCentral

25.

Zhang X, Claerhout S, Prat A et al (2013) A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res 73:4885–4897. https://doi.org/10.1158/0008-5472.CAN-12-4081 CrossRefPubMedPubMedCentral

26.

Marangoni E, Vincent-Salomon A, Auger N et al (2007) A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res 13:3989–3998. https://doi.org/10.1158/1078-0432.CCR-07-0078 CrossRefPubMed

27.

Ding L, Ellis MJ, Li S et al (2010) Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464:999–1005. https://doi.org/10.1038/nature08989 CrossRefPubMedPubMedCentral

28.

DeRose YS, Gligorich KM, Wang G et al (2013) Patient-derived models of human breast cancer: protocols for in vitro and in vivo applications in tumor biology and translational medicine. Curr Protoc Pharmacol Chapter 14(Unit14):23. https://doi.org/10.1002/0471141755.ph1423s60 CrossRef

29.

Neve RM, Chin K, Fridlyand J et al (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10:515–527. https://doi.org/10.1016/j.ccr.2006.10.008 CrossRefPubMedPubMedCentral

30.

Kao J, Salari K, Bocanegra M et al (2009) Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS ONE. https://doi.org/10.1371/journal.pone.0006146 CrossRefPubMedPubMedCentral

31.

Tsuji K, Kawauchi S, Saito S et al (2010) Breast cancer cell lines carry cell line-specific genomic alterations that are distinct from aberrations in breast cancer tissues: comparison of the CGH profiles between cancer cell lines and primary cancer tissues. BMC Cancer. https://doi.org/10.1186/1471-2407-10-15 PubMedPubMedCentralCrossRef

32.

Bruna A, Rueda OM, Greenwood W et al (2016) A biobank of breast cancer explants with preserved intra-tumor heterogeneity to screen anticancer compounds. Cell 167(260–274):e22. https://doi.org/10.1016/j.cell.2016.08.041 CrossRef

33.

Kuroda Y, Wakao S, Kitada M et al (2013) Isolation, culture and evaluation of multilineage-differentiating stress-enduring (Muse) cells. Nat Protoc 8:1391–1415. https://doi.org/10.1038/nprot.2013.076 CrossRefPubMed

34.

Byrski T, Dent R, Blecharz P et al (2012) Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer. Breast Cancer Res 14:R110. https://doi.org/10.1186/bcr3231 CrossRefPubMedPubMedCentral

35.

Turner NC, Tutt ANJ (2012) Platinum chemotherapy for BRCA1-related breast cancer: do we need more evidence? Breast Cancer Res 14:115. https://doi.org/10.1186/bcr3332 CrossRefPubMedPubMedCentral

36.

Baker BM, Chen CS (2012) Deconstructing the third dimension: how 3D culture microenvironments alter cellular cues. J Cell Sci 125:3015–3024. https://doi.org/10.1242/jcs.079509 CrossRefPubMedPubMedCentral

37.

Xu X, Farach-Carson MC, Jia X (2014) Three-dimensional in vitro tumor models for cancer research and drug evaluation. Biotechnol Adv 32:1256–1268. https://doi.org/10.1016/j.biotechadv.2014.07.009 CrossRefPubMedPubMedCentral

38.

Theodoraki MA, Rezende CO, Chantarasriwong O et al (2015) Spontaneously-forming spheroids as an in vitro cancer cell model for anticancer drug screening. Oncotarget 6:21255–21267. https://doi.org/10.18632/oncotarget.4013 CrossRefPubMedPubMedCentral

39.

Breithaupt H, Dammann A, Aigner K (1982) Pharmacokinetics of dacarbazine (DTIC) and its metabolite 5-aminoimidazole-4-carboxamide (AIC) following different dose schedules. Cancer Chemother Pharmacol 9:103–109CrossRefPubMed

40.

Li S, Shen D, Shao J et al (2013) Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep 4:1116–1130. https://doi.org/10.1016/j.celrep.2013.08.022 CrossRefPubMed

41.

Ogawa K, Yoshii Y, Nishimaki T et al (2008) Treatment and prognosis of brain metastases from breast cancer. J Neurooncol 86:231–238. https://doi.org/10.1007/s11060-007-9469-1 CrossRefPubMed

42.

Lee SS, Ahn J-H, Kim MK et al (2008) Brain metastases in breast cancer: prognostic factors and management. Breast Cancer Res Treat 111:523–530. https://doi.org/10.1007/s10549-007-9806-2 CrossRefPubMed

43.

Zhou H, Zhao D (2014) Ultrasound imaging-guided intracardiac injection to develop a mouse model of breast cancer brain metastases followed by longitudinal MRI. J Vis Exp. https://doi.org/10.3791/51146 CrossRefPubMedPubMedCentral

44.

Percy DB, Ribot EJ, Chen Y et al (2011) In vivo characterization of changing blood-tumor barrier permeability in a mouse model of breast cancer metastasis: a complementary magnetic resonance imaging approach. Invest Radiol 46:718–725. https://doi.org/10.1097/RLI.0b013e318226c427 PubMedCrossRef

45.

Bos PD, Zhang XH-F, Nadal C et al (2009) Genes that mediate breast cancer metastasis to the brain. Nature 459:1005–1009. https://doi.org/10.1038/nature08021 CrossRefPubMedPubMedCentral

46.

Boisdron-Celle M, Lebouil A, Allain P, Gamelin E (2001) Pharmacokinetic properties of platinium derivatives. Bull Cancer 88:14–19

47.

Genka S, Deutsch J, Stahle PL et al (1990) Brain and plasma pharmacokinetics and anticancer activities of cyclophosphamide and phosphoramide mustard in the rat. Cancer Chemother Pharmacol 27:1–7CrossRefPubMed

48.

Arndt CA, Balis FM, McCully CL et al (1988) Cerebrospinal fluid penetration of active metabolites of cyclophosphamide and ifosfamide in rhesus monkeys. Cancer Res 48:2113–2115PubMed

49.

Livasy CA, Karaca G, Nanda R et al (2006) Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 19:264–271. https://doi.org/10.1038/modpathol.3800528 CrossRefPubMed

50.

Polioudaki H, Agelaki S, Chiotaki R et al (2015) Variable expression levels of keratin and vimentin reveal differential EMT status of circulating tumor cells and correlation with clinical characteristics and outcome of patients with metastatic breast cancer. BMC Cancer 15:399. https://doi.org/10.1186/s12885-015-1386-7 CrossRefPubMedPubMedCentral

51.

Thompson EW, Paik S, Brünner N et al (1992) Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J Cell Physiol 150:534–544. https://doi.org/10.1002/jcp.1041500314 CrossRefPubMed

52.

Hendrix MJ, Seftor EA, Seftor RE, Trevor KT (1997) Experimental co-expression of vimentin and keratin intermediate filaments in human breast cancer cells results in phenotypic interconversion and increased invasive behavior. Am J Pathol 150:483–495PubMedPubMedCentral

53.

Calvo JL, Carbonell AL, Boya J (1991) Co-expression of glial fibrillary acidic protein and vimentin in reactive astrocytes following brain injury in rats. Brain Res 566:333–336CrossRefPubMed

54.

Pekny M, Nilsson M (2005) Astrocyte activation and reactive gliosis. Glia 50:427–434. https://doi.org/10.1002/glia.20207 CrossRefPubMed

55.

Lorger M, Felding-Habermann B (2010) Capturing changes in the brain microenvironment during initial steps of breast cancer brain metastasis. Am J Pathol 176:2958–2971. https://doi.org/10.2353/ajpath.2010.090838 CrossRefPubMedPubMedCentral

56.

Chambers AF, Groom AC, MacDonald IC (2002) Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2:563–572. https://doi.org/10.1038/nrc865 CrossRefPubMed

57.

Sirica AE, Gores GJ (2014) Desmoplastic stroma and cholangiocarcinoma: clinical implications and therapeutic targeting. Hepatology 59:2397–2402. https://doi.org/10.1002/hep.26762 CrossRefPubMedPubMedCentral

58.

McMillin DW, Negri JM, Mitsiades CS (2013) The role of tumour-stromal interactions in modifying drug response: challenges and opportunities. Nat Rev Drug Discov 12:217–228. https://doi.org/10.1038/nrd3870 CrossRefPubMed

59.

Bichat F, Mouawad R, Solis-Recendez G et al (1997) Cytoskeleton alteration in MCF7R cells, a multidrug resistant human breast cancer cell line. Anticancer Res 17:3393–3401PubMed

60.

Sommers CL, Heckford SE, Skerker JM et al (1992) Loss of epithelial markers and acquisition of vimentin expression in adriamycin- and vinblastine-resistant human breast cancer cell lines. Cancer Res 52:5190–5197PubMed

61.

Arumugam T, Ramachandran V, Fournier KF et al (2009) Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res 69:5820–5828. https://doi.org/10.1158/0008-5472.CAN-08-2819 CrossRefPubMedPubMedCentral

62.

Lazarova DL, Bordonaro M (2016) Vimentin, colon cancer progression and resistance to butyrate and other HDACis. J Cell Mol Med 20:989–993. https://doi.org/10.1111/jcmm.12850 CrossRefPubMedPubMedCentral

63.

Hu Y, Zang J, Qin X et al (2017) Epithelial-to-mesenchymal transition correlates with gefitinib resistance in NSCLC cells and the liver X receptor ligand GW3965 reverses gefitinib resistance through inhibition of vimentin. Onco Targets Ther 10:2341–2348. https://doi.org/10.2147/OTT.S124757 CrossRefPubMedPubMedCentral

64.

Casasent AK, Schalck A, Gao R et al (2018) Multiclonal invasion in breast tumors identified by topographic single cell sequencing. Cell 172(205–217):e12. https://doi.org/10.1016/j.cell.2017.12.007 CrossRef

65.

Hoadley KA, Siegel MB, Kanchi KL et al (2016) Tumor evolution in two patients with basal-like breast cancer: a retrospective genomics study of multiple metastases. PLoS Med 13:e1002174. https://doi.org/10.1371/journal.pmed.1002174 CrossRefPubMedPubMedCentral

66.

Avigdor BE, Cimino-Mathews A, DeMarzo AM et al (2017) Mutational profiles of breast cancer metastases from a rapid autopsy series reveal multiple evolutionary trajectories. JCI Insight. https://doi.org/10.1172/jci.insight.96896 PubMedPubMedCentralCrossRef

67.

Savas P, Teo ZL, Lefevre C et al (2016) The subclonal architecture of metastatic breast cancer: results from a prospective community-based rapid autopsy program “CASCADE”. PLoS Med 13:e1002204. https://doi.org/10.1371/journal.pmed.1002204 CrossRefPubMedPubMedCentral

68.

Gao H, Korn JM, Ferretti S et al (2015) High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nat Med 21:1318–1325. https://doi.org/10.1038/nm.3954 CrossRefPubMed

Title: Characterizing the efficacy of cancer therapeutics in patient-derived xenograft models of metastatic breast cancer
Authors: Tia H. Turner
Mohammad A. Alzubi
Sahib S. Sohal
Amy L. Olex
Mikhail G. Dozmorov
J. Chuck Harrell
Publication date: 01-07-2018
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2018
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-018-4748-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2018

A parallel model for breast cancer metastasis

Breast cancer survival, survival disparities, and guideline-based treatment

Prediction of breast cancer risk with volatile biomarkers in breath

Radial scar on image-guided breast biopsy: is surgical excision necessary?

GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer

Thirty-day postoperative morbidity and mortality in elderly women with breast cancer: an analysis of the NSQIP database

Keynote webinar | Spotlight on antibody–drug conjugates in cancer